Literature DB >> 16427280

Carriers and patients with muscle-eye-brain disease can be rapidly diagnosed by enzymatic analysis of fibroblasts and lymphoblasts.

Jiri Vajsar1, Wenli Zhang, William B Dobyns, Doug Biggar, Kenton R Holden, Cynthia Hawkins, Peter Ray, Ann H Olney, Catherine M Burson, Anand K Srivastava, Harry Schachter.   

Abstract

We report a new fibroblast and lymphoblast based protein O-mannosyl beta-1,2-N-acetylglucosaminyltransferase 1 enzymatic assay, which allows rapid and accurate diagnosis of carriers and patients with muscle-eye-brain type of congenital muscular dystrophy. Seven patients with genetically confirmed muscle-eye-brain disease were assayed for protein O-mannosyl beta-1,2-N-acetylglucosaminyltransferase 1 enzyme activity. In three patients and their heterozygous parents, the assays were done on EBV-transformed lymphoblasts, in another three patients they were done on cultured fibroblasts and in the last patient on both fibroblasts and lymphoblasts. Cultured fibroblasts and lymphoblasts from the muscle-eye-brain patients showed a highly significant decrease in protein O-mannosyl beta-1,2-N-acetylglucosaminyltransferase 1 activity relative to controls. The residual protein O-mannosyl beta-1,2-N-acetylglucosaminyltransferase 1 level in fibroblasts (average 0.11 nmoles/h per mg) was about 13% of normal controls. The ratio of protein O-mannosyl beta-1,2-N-acetylglucosaminyltransferase 1 activity to the activity of a glycosyltransferase control (N-acetylglucosaminyltransferase 1; GnT1) in fibroblasts was on average 0.006 in muscle-eye-brain patients and 0.045 in controls. The average residual protein O-mannosyl beta-1,2-N-acetylglucosaminyltransferase 1 level in lymphoblasts was 15% of normal controls. The average ratio of protein O-mannosyl beta-1,2-N-acetylglucosaminyltransferase 1/GnT1 activity was 0.007 in muscle-eye-brain patients, 0.026 in heterozygous carriers and 0.046 in normal controls. Assay of protein O-mannosyl beta-1,2-N-acetylglucosaminyltransferase 1 activity in fibroblasts and lymphoblasts from muscle-eye-brain carriers and patients provides a rapid and relatively simple diagnostic test for this disease and could be used as a screening test in carriers and patients with complex congenital muscular dystrophy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16427280     DOI: 10.1016/j.nmd.2005.11.012

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  7 in total

Review 1.  The congenital muscular dystrophies: recent advances and molecular insights.

Authors:  Jerry R Mendell; Daniel R Boué; Paul T Martin
Journal:  Pediatr Dev Pathol       Date:  2006 Nov-Dec

Review 2.  Mechanisms of disease: congenital muscular dystrophies-glycosylation takes center stage.

Authors:  Paul T Martin
Journal:  Nat Clin Pract Neurol       Date:  2006-04

Review 3.  Dissecting the molecular basis of the role of the O-mannosylation pathway in disease: α-dystroglycan and forms of muscular dystrophy.

Authors:  David Live; Lance Wells; Geert-Jan Boons
Journal:  Chembiochem       Date:  2013-11-07       Impact factor: 3.164

4.  Endogenous glucuronyltransferase activity of LARGE or LARGE2 required for functional modification of α-dystroglycan in cells and tissues.

Authors:  Kei-ichiro Inamori; Tobias Willer; Yuji Hara; David Venzke; Mary E Anderson; Nigel F Clarke; Pascale Guicheney; Carsten G Bönnemann; Steven A Moore; Kevin P Campbell
Journal:  J Biol Chem       Date:  2014-08-19       Impact factor: 5.157

5.  Mouse fukutin deletion impairs dystroglycan processing and recapitulates muscular dystrophy.

Authors:  Aaron M Beedle; Amy J Turner; Yoshiaki Saito; John D Lueck; Steven J Foltz; Marisa J Fortunato; Patricia M Nienaber; Kevin P Campbell
Journal:  J Clin Invest       Date:  2012-08-27       Impact factor: 14.808

6.  Novel POMGnT1 mutations define broader phenotypic spectrum of muscle-eye-brain disease.

Authors:  Ute Hehr; Goekhan Uyanik; Claudia Gross; Maggie C Walter; Axel Bohring; Monika Cohen; Barbara Oehl-Jaschkowitz; Lynne M Bird; Ghiat M Shamdeen; Ulrich Bogdahn; Gerhard Schuierer; Haluk Topaloglu; Ludwig Aigner; Hanns Lochmüller; Jürgen Winkler
Journal:  Neurogenetics       Date:  2007-09-29       Impact factor: 2.660

Review 7.  Dystroglycan glycosylation and its role in alpha-dystroglycanopathies.

Authors:  T Endo
Journal:  Acta Myol       Date:  2007-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.